3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
5
Ovarian Neoplasms
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Hereditary Breast and Ovarian Cancer Syndrome
2
Urogenital Neoplasms
1
Sarcoma
1
Pancreatic Neoplasms
1
Neoplastic Syndromes, Hereditary
1
Neoplasms, Unknown Primary
1
Melanoma
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Fanconi Anemia, Complementation Group D1
1
Digestive System Neoplasms
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Brain Neoplasms
1
Interventions
pembrolizumab
9
Cyclophosphamide
6
fludarabine phosphate
4
aldesleukin
3
Radiotherapy
3
Gemcitabine
3
Drug Therapy
3
Docetaxel
3
Cetuximab
3
temsirolimus
2
sargramostim
2
motexafin gadolinium
2
liposomal doxorubicin
2
fludarabine
2
entinostat
2
durvalumab
2
belinostat
2
atezolizumab
2
Sirolimus
2
Paclitaxel
2
Methods
2
Metformin
2
Irinotecan
2
Interferon-alpha
2
Bortezomib
2
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
2
valspodar
1
tremelimumab
1
tocilizumab
1
tanespimycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Genetic Counseling
×
Breast
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled